ABSTRACT
Objective Germline pathogenic variants (PVs) in the DNA mismatch repair (MMR) genes and the base excision repair genes NTHL1 and MUTYH underlie hereditary CRC and polyposis syndromes. We evaluate the robustness and discriminatory potential of tumour mutational signatures in colorectal cancers (CRCs) for identifying germline PV carriers.
Design Whole exome sequencing of FFPE CRC tissue was performed on hereditary CRC PV carriers (14 MMR, 6 biallelic MUTYH, and 1 biallelic NTHL1), 9 sporadic MMR-deficient CRCs (MMRd controls) and 18 sporadic MMR-proficient CRCs (MMRp controls). COSMIC V3 Single Base Substitution (SBS) and Indel (ID) mutational signatures were calculated and assessed for their ability to differentiate CRCs that developed in carriers and non-carriers.
Results The combination of SBS18 and SBS36 contributing >23% of the signature profile was able to discriminate biallelic MUTYH carriers from MMRp and MMRd control CRCs with >99% confidence. Variant specific signatures SBS18 and SBS36 were identified for MUTYH p.Gly396Asp (p=0.015) and MUTYH p.Tyr179Cys (p=0.0012), respectively. SBS30 was significantly increased in a CRC from a biallelic NTHL1 carrier compared with MMRp and MMRd control CRCs. The combination of ID2, ID7, SBS15 and SBS1 could discriminate the 14 MMR PV carrier CRCs from the MMRp control CRCs, however, SBS and ID signatures, alone or in combination, could not provide complete discrimination between CRCs from MMR PV carriers and sporadic MMRd controls.
Conclusion Assessment of SBS and ID signatures can discriminate CRCs from MUTYH, NTHL1 and MMR PV carriers from non-carriers, demonstrating utility as a potential diagnostic and variant classification tool.
What is already known about this subject?
Identifying carriers of pathogenic variants (PVs) in moderate/high-risk CRC and polyposis susceptibility genes has clinical relevance for diagnosis, targeted screening and prevention strategies, prognosis, and treatment options, however, challenges still remain in the identification of carriers and the classification of rare variants in these genes.
Previous studies have identified tumour mutational signatures that result from defective DNA repair including DNA mismatch repair (MMR) deficiency and base excision repair defects, DNA repair mechanisms that underlie the common hereditary CRC and polyposis syndromes.
What are the new findings?
Single base substitution (SBS)-related mutational signatures derived from whole exome sequencing of FFPE-derived CRC tissue DNA could effectively discriminate CRCs that developed in biallelic MUTYH PV carriers and biallelic NTHL1 PV carriers from CRC-affected non-carriers.
CRCs that developed in MMR PV carriers (Lynch syndrome) could be effectively differentiated from sporadic MMR-proficient CRC by a combination of SBS and indel (ID) signatures, but they were less effective at discriminating Lynch syndrome-related CRC from sporadic MMR-deficient CRC resulting from MLH1 gene promoter hypermethylation.
The SBS and ID mutational signatures associated with hereditary CRC and polyposis syndrome carriers were robust to changes in experimental settings.
We demonstrate the optimal variant filtering settings for calculating mutational signatures and define stringent thresholds for classifying CRC aetiology as hereditary or non-hereditary.
How might it impact on clinical practice in the foreseeable future?
Deriving SBS- and ID-related mutational signatures from CRCs can identify carriers of PVs in hereditary CRC and polyposis susceptibility genes.
The application of mutational signatures will improve the diagnosis of syndromic CRC and aid in variant classification, leading to improved clinical management and CRC prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding by a National Health and Medical Research Council of Australia (NHMRC) project grant 1125269 (PI- Daniel Buchanan), supported the design, analysis and interpretation of data. DDB is supported by a NHMRC R.D. Wright Career Development Fellowship and funding from the University of Melbourne Research at Melbourne Accelerator Program (R@MAP). PG is supported by an Australian Government Research Training Program Scholarship. BP is supported by a Victorian Health and Medical Research Fellowship Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA167551 and through a cooperative agreement with the Australasian Colorectal Cancer Family Registry (NCI/NIH U01 CA074778 and U01/U24 CA097735) and by the Victorian Cancer Registry, Australia. This research was performed under CCFR approved projects C-AU-0818-01, C-AU-1014-02, C-AU-0312-01, C-AU-1013-02.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.